MX2021004183A - Composiciones y metodos para el tratamiento de la presbicia. - Google Patents

Composiciones y metodos para el tratamiento de la presbicia.

Info

Publication number
MX2021004183A
MX2021004183A MX2021004183A MX2021004183A MX2021004183A MX 2021004183 A MX2021004183 A MX 2021004183A MX 2021004183 A MX2021004183 A MX 2021004183A MX 2021004183 A MX2021004183 A MX 2021004183A MX 2021004183 A MX2021004183 A MX 2021004183A
Authority
MX
Mexico
Prior art keywords
container
methods
presbyopia
treatment
compositions
Prior art date
Application number
MX2021004183A
Other languages
English (en)
Inventor
Gerald Horn
Original Assignee
Presbyopia Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Presbyopia Therapies Inc filed Critical Presbyopia Therapies Inc
Publication of MX2021004183A publication Critical patent/MX2021004183A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/1412—Containers with closing means, e.g. caps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Abstract

La invención provee composiciones y métodos para el tratamiento de la presbicia; los métodos comprenden de preferencia almacenar una composición de aceclidina en un recipiente que tiene un espacio superior a una temperatura de aproximadamente 2 a 5 aproximadamente 8 grados Celsius; los métodos comprenden adicionalmente llenar el recipiente bajo una cubierta de gas inerte y/o encerrar el recipiente con un material anti-lixiviación o disponer el recipiente en un segundo recipiente que contiene un material anti-lixiviación.
MX2021004183A 2018-10-10 2019-10-08 Composiciones y metodos para el tratamiento de la presbicia. MX2021004183A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862743720P 2018-10-10 2018-10-10
PCT/US2019/055116 WO2020076769A1 (en) 2018-10-10 2019-10-08 Compositions and methods for the treatment of presbyopia

Publications (1)

Publication Number Publication Date
MX2021004183A true MX2021004183A (es) 2021-10-26

Family

ID=70161531

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021004183A MX2021004183A (es) 2018-10-10 2019-10-08 Composiciones y metodos para el tratamiento de la presbicia.

Country Status (12)

Country Link
US (1) US10836760B2 (es)
EP (1) EP3863630A4 (es)
JP (1) JP2022504746A (es)
KR (1) KR20210076941A (es)
CN (1) CN113518620A (es)
AU (1) AU2019357979A1 (es)
BR (1) BR112021006618B1 (es)
CA (1) CA3114204A1 (es)
MA (1) MA53873A (es)
MX (1) MX2021004183A (es)
SG (1) SG11202103033WA (es)
WO (1) WO2020076769A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021222525A1 (en) * 2020-04-30 2021-11-04 Eye Therapies, Llc Brimonidine compositions and methods of use
CA3195422A1 (en) * 2020-10-13 2022-04-21 Gerald Horn Compositions and methods for storage stable ophthalmic drugs
WO2022232205A1 (en) * 2021-04-28 2022-11-03 Lenz Therapeutics, Inc. A method of reducing brow ache
CN116459251A (zh) * 2022-01-18 2023-07-21 苏州普乐康医药科技有限公司 一种含西维美林的眼用制剂及其制备方法和应用
TW202329958A (zh) * 2022-01-25 2023-08-01 張金明 西維美林水溶液組合物和使用方法
US20230310380A1 (en) * 2022-04-05 2023-10-05 Alan Neil Glazier Methods, devices, and systems for treating lens protein aggregation diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994001096A1 (en) * 1992-07-02 1994-01-20 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
US20090297566A1 (en) * 2004-12-27 2009-12-03 Brinkman Kyle R Oxygen-impervious packaging with optional oxygen scavenger, stabilized thyroid hormone compositions and methods for storing thyroid hormone pharmaceutical compositions
US20190038609A1 (en) * 2013-08-28 2019-02-07 Presbyopia Therapies, LLC Compositions and methods for the treatment of presbyopia
US9320709B2 (en) * 2013-08-28 2016-04-26 Presbyopia Therapies Llc Storage stable compositions and methods for the treatment of refractive errors of the eye
US10307408B2 (en) * 2013-08-28 2019-06-04 Presbyopia Therapies, LLC Contact lens compositions and methods for the treatment of presbyopia

Also Published As

Publication number Publication date
MA53873A (fr) 2022-01-19
US20200115377A1 (en) 2020-04-16
CN113518620A (zh) 2021-10-19
CA3114204A1 (en) 2020-04-16
WO2020076769A1 (en) 2020-04-16
BR112021006618A2 (pt) 2021-07-06
BR112021006618B1 (pt) 2022-09-27
EP3863630A4 (en) 2022-06-29
US10836760B2 (en) 2020-11-17
EP3863630A1 (en) 2021-08-18
SG11202103033WA (en) 2021-04-29
JP2022504746A (ja) 2022-01-13
KR20210076941A (ko) 2021-06-24
AU2019357979A1 (en) 2021-04-29

Similar Documents

Publication Publication Date Title
MX2021004183A (es) Composiciones y metodos para el tratamiento de la presbicia.
PH12017550099A1 (en) Composition suitable for protecting microorganisms
MA40028A (fr) Compositions détergentes en doses unitaires
PH12019502406A1 (en) Aerosol generating apparatus and cradle capable of receiving same
MX2016003684A (es) Metodo, dispositivo y dispositivo electronico para calentar un contenedor de un equipo de coccion por induccion.
PH12019501540A1 (en) Composition comprising cinmethylin-containing microparticles and a further herbicide
MY197758A (en) Methods for treating conditions associated with masp-2 dependent complement activation
MX2021001550A (es) Inhibidores de transglutaminasa 2 (tg2).
MX2016010691A (es) Hidroclorofluoroolefinas e hidrofluoroolefinas estabilizadas.
MX2017016517A (es) Composiciones estables al almacenamiento y metodos para el tratamiento de errores de refraccion del ojo.
MX2017013488A (es) Una composicion.
MX2018015298A (es) Metodo para estabilizar proteinas.
MY182833A (en) Apparatus and methods for labeling vials or ampoules stored at temperatures as low as -200 ?c
MX2018010989A (es) Sustitutos de crema liquidos basados en plantas con hidrocoloides naturales.
MX2013013170A (es) Cierres libres de pvc.
UA122488C2 (uk) Композиція для підвищення ефективності приживання гемопоетичних стовбурових клітин після трансплантації
MX367374B (es) Composiciones antitranspirantes en barra solida que tienen siliconas no volatiles.
MY176416A (en) Sintered zircon material for forming block
SG11201811088PA (en) Hydrogen sulfide mixture, method for producing same, and filling container
MX2017005183A (es) Metodo de tratamiento para antibrote de tuberculos con cantidad reducida de cipc.
SG11201907190SA (en) Shea olein and method for preparing same
PT3422858T (pt) Composição de bioestimulação para o crescimento de plantas que contêm lipopeptidos
MY196338A (en) Packaged Beverage
MX2020003598A (es) Composicion de material de revestimiento a base de yeso para moldeo y metodo de fabricacion de composicion de material de revestimiento a base de yeso para moldeo.
SA518400037B1 (ar) -n،n تــركــيــبـة أكـريـلات ثـنـائـي مـيـثـيـل أمـيـن الإيـثـيـل مـثـبـتـة فـيـمـا يـتـعـلـق بـآثـار تـغـيـر الـلـون